Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

InvestigationalLater-Stage Human

Cancer type: Liver Cancer
Trial identifier: NCT06109272
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Hepatocellular Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-22

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-22

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06109272 (opens in a new tab) (Clinical-trial registry) NCT06109272 Load-bearing source NCT06109272
ClinicalTrials.gov — NCT06109272. NCT06109272.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

InvestigationalLater-Stage Human

Cancer type: Pancreatic Cancer
Trial identifier: NCT07409272
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-22

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-22

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07409272 (opens in a new tab) (Clinical-trial registry) NCT07409272 Load-bearing source NCT07409272
ClinicalTrials.gov — NCT07409272. NCT07409272.

Eligibility varies — review trial criteria.

Trial Watch: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

InvestigationalLater-Stage Human

Cancer type: Prostate Cancer
Trial identifier: NCT06855277
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 100 Years with Prostate Cancer who meet the study-specific registry eligibility criteria; sex eligibility: male.
Last reviewed: 2026-09-22

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-22

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06855277 (opens in a new tab) (Clinical-trial registry) NCT06855277 Load-bearing source NCT06855277
ClinicalTrials.gov — NCT06855277. NCT06855277.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

InvestigationalLater-Stage Human

Cancer type: Lymphoma
Trial identifier: NCT06549595
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 130 Years with Untreated Follicular Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06549595 (opens in a new tab) (Clinical-trial registry) NCT06549595 Load-bearing source NCT06549595
ClinicalTrials.gov — NCT06549595. NCT06549595.

Eligibility varies — review trial criteria.

Trial Watch: Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT06732401
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06732401 (opens in a new tab) (Clinical-trial registry) NCT06732401 Load-bearing source NCT06732401
ClinicalTrials.gov — NCT06732401. NCT06732401.

Eligibility varies — review trial criteria.

Trial Watch: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

InvestigationalLater-Stage Human

Cancer type: Breast Cancer
Trial identifier: NCT06058377
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-18

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-18

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06058377 (opens in a new tab) (Clinical-trial registry) NCT06058377 Load-bearing source NCT06058377
ClinicalTrials.gov — NCT06058377. NCT06058377.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

InvestigationalLater-Stage Human

Cancer type: Breast Cancer
Trial identifier: NCT07827573
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-18

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-18

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07827573 (opens in a new tab) (Clinical-trial registry) NCT07827573 Load-bearing source NCT07827573
ClinicalTrials.gov — NCT07827573. NCT07827573.

Eligibility varies — review trial criteria.

Trial Watch: Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

InvestigationalLater-Stage Human

Cancer type: Brain / CNS Cancer
Trial identifier: NCT07195591
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Glioblastoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-18

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-18

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07195591 (opens in a new tab) (Clinical-trial registry) NCT07195591 Load-bearing source NCT07195591
ClinicalTrials.gov — NCT07195591. NCT07195591.

Eligibility varies — review trial criteria.

Trial Watch: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

InvestigationalLater-Stage Human

Cancer type: Leukemia, Lymphoma
Trial identifier: NCT04269902
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-17

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-17

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT04269902 (opens in a new tab) (Clinical-trial registry) NCT04269902 Load-bearing source NCT04269902
ClinicalTrials.gov — NCT04269902. NCT04269902.

Eligibility varies — review trial criteria.

Trial Watch: BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT07625644
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-09-17

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-09-17

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07625644 (opens in a new tab) (Clinical-trial registry) NCT07625644 Load-bearing source NCT07625644
ClinicalTrials.gov — NCT07625644. NCT07625644.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.